TLDR: QInscribe, a new medical writing service, has officially launched, leveraging generative Artificial Intelligence (AI) to reduce the time required to produce a draft Clinical Study Report (CSR) by an impressive 90%, from a traditional 50-100 hours down to just 5 hours.
LONDON – September 29, 2025 – A significant advancement in medical writing has emerged with the official launch of QInscribe, a new service brand poised to revolutionize the creation of regulatory and scientific documents. QInscribe is introducing generative Artificial Intelligence (AI) driven solutions aimed at drastically reducing the time and effort involved in generating critical clinical trial documentation, most notably the Clinical Study Report (CSR).
The core of QInscribe’s offering lies in its ability to produce high-quality first-draft regulatory documents at unprecedented speeds. The company states that its advanced AI-supported workflows can cut the time to generate a draft CSR by 90%. Traditionally, this complex and labor-intensive process could take approximately 50 to 100 hours. With QInscribe’s innovative approach, this can now be accomplished in as little as 5 hours, an efficiency that will directly benefit its pharmaceutical and biotechnology clients.
Amol Hule, Associate Director of Medical Writing at QInscribe, emphasized the transformative potential of this technology. “Medical writing can benefit from the AI revolution that is reshaping industries worldwide. It can still uphold the highest quality standards that you would expect, but in a fraction of the time,” Hule stated. He further elaborated on the company’s methodology: “We combine specialist human insight from a team of experienced medical writers with AI-enabled efficiencies to ensure every deliverable is accurate, consistent, and submission-ready.”
The launch comes at a time when pharmaceutical and biotechnology companies are under increasing pressure to streamline regulatory submissions, improve document consistency, and accelerate drug development timelines. QInscribe’s specialized model is built for scale, enabling it to support large volumes and tight turnaround requests, addressing a critical need in the industry.
Also Read:
- Visa Unveils New AI-Powered Commercial Solutions Hub to Bolster Offerings
- Paper2Agent Initiative Transforms Scientific Research into Interactive AI Agents
Beyond CSRs, QInscribe provides a comprehensive suite of services across regulatory medical writing, scientific writing, and clinical trial transparency. The company partners with biopharmaceutical firms of all sizes, from emerging biotech startups to established global sponsors, delivering documents with a focus on accuracy, speed, and strategic insight, all powered by its unique combination of expert-led services and AI-supported workflows.
